BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.

BACKGROUND: The relationship between thyroid status, including subclinical hypothyroidism (SH) and serum leptin is controversial or uncertain.

Therefore we evaluated serum leptin in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT(4)) replacement on serum leptin in these disorders.

METHODS: Serum leptin, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women.

In addition, the effect of LT(4) treatment on serum leptin in SH and OH was assessed.

RESULTS: The mean +/- SD (median) serum leptin concentrations in the OH and SH groups were higher than in the EU group (35.1 +/- 27.2 [33.0] and 36.6 +/- 21.9 [30.6] ng/mL, respectively, vs. 23.2 +/- 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women.

In premenopausal women there was no correlation between leptin, BMI, or FMI and serum TSH levels (r(s) = 0.009, p = 0.474; r(s) = 0.043, p = 0.367; r(s) = 0.092, p = 0.232).

In the postmenopausal women, the partial correlation coefficient between TSH and leptin was present, even when controlling for BMI (r(s) = 0.297, p = 0.042) and FMI (r(s) = 0.275, p = 0.050).

LT(4) treatment was associated with a reduction of serum leptin concentrations in the OH group (p = 0.008).

In SH group there were no differences between LT(4) replacement or no treatment, since a fall in serum leptin levels was detected in both SH subgroups, despite a more pronounced fall with LT(4) use.

CONCLUSIONS: Serum leptin concentrations are elevated in postmenopausal women with SH or OH.

A relationship between thyroid status and serum leptin is further supported by the fact that LT(4) treatment, to restore the EU status, reduced serum leptin levels in OH in the absence of significant effects on BMI.

In women, hypothyroidism influences either leptin secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.

[MeSH-major] Body Composition. Hormone Replacement Therapy. Hypothyroidism / drug therapy. Leptin / blood. Postmenopause / blood. Premenopause / blood. Thyroxine / therapeutic use

MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

MedlinePlus Health Information. consumer health - Hypothyroidism.

Hazardous Substances Data Bank. LEVOTHYROXINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19415994.001).

[ISSN] 1557-9077

[Journal-full-title] Thyroid : official journal of the American Thyroid Association

[ISO-abbreviation] Thyroid

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.

In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support.

Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment.

The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients.

In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.

Hazardous Substances Data Bank. NITRIC OXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19057612.001).

[ISSN] 1476-5543

[Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association

[ISO-abbreviation] J Perinatol

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.

There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL).

This agent has a high degree of activity against a variety of tumor cell lines.

Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]

[Cites] Anticancer Drugs. 2005 Sep;16(8):871-7 [16096436.001]

[Cites] J Clin Oncol. 2009 Feb 10;27(5):812-26 [19103723.001]

[Cites] Ther Clin Risk Manag. 2008 Aug;4(4):727-32 [19209254.001]

[Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]

[Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]

[Cites] Biochim Biophys Acta. 1972 Dec 22;287(3):386-9 [4629776.001]

[Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4 [12170426.001]

[Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]

[Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12 [16402269.001]

[Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]

[Cites] Cancer Chemother Pharmacol. 2007 May;59(6):759-70 [16957931.001]

[Cites] Anticancer Drugs. 2007 Jun;18(5):587-95 [17414628.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]

[Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]

[Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]

[Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53 [17653574.001]

[Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S13-7 [18282361.001]

[Cites] Blood. 2008 Jul 15;112(2):330-9 [18451308.001]

[Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):227-34 [18719942.001]

[Cites] Blood. 2008 Oct 1;112(7):2596-7 [18809766.001]

[Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]

[Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]

[Cites] Pharmazie. 1985 Nov;40(11):782-4 [4095129.001]

[Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]

[Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11 [12170425.001]

[Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]

[Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]

[Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]

[Cites] J Clin Oncol. 2005 Nov 1;23(31):7985-93 [16204016.001]

[Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104 [16292542.001]

[Cites] Br J Cancer. 2007 Jun 4;96(11):1692-8 [17486132.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]

[Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]

[Cites] Leukemia. 2002 Oct;16(10):2096-105 [12357363.001]

[Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]

[Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]

[Cites] Leuk Lymphoma. 2004 May;45(5):911-3 [15291348.001]

[Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]

[Cites] Haematologica. 2001 May;86(5):485-93 [11410411.001]

[Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]

[Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]

[Cites] Leuk Lymphoma. 2002 Feb;43(2):327-31 [11999564.001]

[Cites] J Cancer Res Clin Oncol. 2002 May;128(5):271-8 [12029443.001]

[Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]

(PMID = 21188134.001).

[ISSN] 1179-1322

[Journal-full-title] Cancer management and research

[ISO-abbreviation] Cancer Manag Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] New Zealand

[Other-IDs] NLM/ PMC3004665

[Keywords] NOTNLM ; Treanda / alkylating agent / bendamustine / chronic lymphocytic lymphoma / indolent non-Hodgkin lymphoma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary manifestation of small lymphocytic lymphoma in the prostate.

BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.

However, primary manifestation of SLL/CLL in the prostate is rarely diagnosed.

PATIENTS AND METHODS: We report two cases of primary prostatic SLL/CLL, in one case in combination with prostate carcinoma, and discuss diagnostic pitfalls, pathophysiological mechanisms and therapeutic management, together with an overview of the literature.

CONCLUSIONS: Lymphocytic infiltration of the prostate associated with obstructive symptoms is rare but can already occur in very early disease.

Microscopically, SLL/CLL infiltration can be distinguished from chronic prostatitis by its pattern of infiltration and by immunohistochemistry.

As the incidence of both SLL/CLL and prostatic carcinoma increases with age, composite tumours might occur more often in the future.

[MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 S. Karger AG, Basel.

[CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]

(PMID = 19816076.001).

[ISSN] 1423-0240

[Journal-full-title] Onkologie

[ISO-abbreviation] Onkologie

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Switzerland

[Number-of-references] 17

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers.

To investigate gender differences, if any, in leptin concentrations from umbilical cord blood of new born infants of mothers with type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery.

Serum leptin concentrations were measured in 105 newborns (53 males and 52 females in the three groups).

Pearson correlation coefficient was used to explore the relationship between serum leptin concentrations and anthropometric measures of the fetus and their mother.

Both Serum leptin level and serum C-peptide was measured by chemiluminescence based ELISA.

The median range of leptin concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)].

Cord serum leptin levels correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord serum C-peptide concentration or placental weight at delivery.

Leptin concentrations were higher in the female fetus in comparison to the male fetus.

We found that there are very strong associations between cord leptin concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with Type 2 DM.

We also found that high leptin levels could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating leptin levels.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochem Biophys Res Commun. 1995 Sep 25;214(3):1260-7 [7575539.001]

[Cites] Eur J Endocrinol. 2001 Jul;145(1):53-8 [11415852.001]

[Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]

[Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]

[Cites] Nat Med. 1996 Sep;2(9):949-50 [8782440.001]

[Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]

[Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]

[Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]

[Cites] J Clin Endocrinol Metab. 1997 May;82(5):1642-4 [9141565.001]

[Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):2849-55 [9284709.001]

[Cites] Eur J Endocrinol. 1997 Dec;137(6):655-8 [9437232.001]

[Cites] Diabetes. 1998 May;47(5):847-50 [9588462.001]

[Cites] Science. 1995 Jul 28;269(5223):540-3 [7624776.001]

(PMID = 20336197.001).

[ISSN] 1998-3832

[Journal-full-title] International journal of diabetes in developing countries

[ISO-abbreviation] Int J Diabetes Dev Ctries

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC2839129

[Keywords] NOTNLM ; Newborn infants / Serum leptin / Type 2 Diabetic / Umbilical cord blood / gestational diabetes mellitus / non diabetic

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.

Diagnosis of two distinct malignant entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.

Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.

Co-occurrence of some carcinomas such as squamous cell carcinoma (SCC), may show especially aggressive behavior.

A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and diffuse lymphadenopathy of the axillary and cervical regions.

FNA of a large cervical lymph node was diagnostic for both atypical lymphocytic proliferation and SCC.

Flow cytometric analysis showed the atypical lymphocytic proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.

These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-cell SLL/CLL.

We report a rare occurrence of metastatic SCC to a lymph node infiltrated by SLL/CLL.

The diagnosis was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of cell block material, and flow cytometry on the sample obtained by FNA.

To the best of our knowledge, only three cases of SCC metastasis to SLL/CLL diagnosed by FNA have been reported in the English literature.

[MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Neoplasms, Multiple Primary / diagnosis. Oropharyngeal Neoplasms / pathology

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18973126.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 16

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The objective is to test the effect of the LAD on pulmonary histopathology in juvenile piglets with acute lung injury caused by saline lung lavage (SLL) followed by intermittent mandatory ventilation (IMV).

Three- to 4-wk-old piglets were randomized to no intervention (control group), SLL alone (SLL group), SLL + IMV (IMV group), or SLL + IMV + LAD (LAD group) (n = 6 per group).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Chest. 1989 Oct;96(4):849-51 [2676391.001]

[Cites] Early Hum Dev. 2008 Nov;84(11):709-16 [18930613.001]

[Cites] J Thorac Cardiovasc Surg. 1993 May;105(5):823-32 [7683735.001]

[Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):838-48; discussion 848-9 [8127113.001]

[Cites] J Pediatr. 1994 Jul;125(1):104-10 [7517446.001]

[Cites] Perfusion. 1994;9(4):265-9 [7981464.001]

[Cites] J Paediatr Child Health. 1995 Apr;31(2):105-11 [7794609.001]

[Cites] Anesthesiology. 1995 Oct;83(4):710-20 [7574050.001]

[Cites] J Pediatr. 1996 Jan;128(1):109-17 [8551400.001]

[Cites] ASAIO J. 1994 Jul-Sep;40(3):M728-31 [8555610.001]

[Cites] Lancet. 1996 Jul 13;348(9020):75-82 [8676720.001]

[Cites] Pediatr Pulmonol. 1996 Oct;22(4):263-70 [8905887.001]

[Cites] J Paediatr Child Health. 1997 Jun;33(3):202-8 [9259293.001]

[Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1058-65 [9351603.001]

[Cites] ASAIO J. 1997 Sep-Oct;43(5):M821-4 [9360161.001]

[Cites] Pediatr Pulmonol Suppl. 1997;16:51 [9443195.001]

[Cites] Ann Thorac Surg. 2000 Feb;69(2):351-6 [10735662.001]

[Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]

[Cites] Intensive Care Med. 2000 Sep;26(9):1334-42 [11089761.001]

[Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):542-51 [11241090.001]

[Cites] Biol Neonate. 2001 Jul;80(1):74-80 [11474154.001]

[Cites] Ann Thorac Surg. 2001 Sep;72(3):899-904 [11570380.001]

[Cites] ASAIO J. 2001 Sep-Oct;47(5):486-91 [11575823.001]

[Cites] J Pediatr. 2001 Oct;139(4):478-86 [11598592.001]

[Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1154-60 [11673202.001]

[Cites] Pediatr Res. 2002 Sep;52(3):387-92 [12193673.001]

[Cites] Ann Thorac Surg. 2002 Oct;74(4):1011-6; discussion 1017-8 [12400738.001]

[Cites] Pediatr Res. 2003 Feb;53(2):245-53 [12538782.001]

[Cites] Crit Care Med. 2003 Mar;31(3):885-92 [12627001.001]

[Cites] Eur Respir J Suppl. 2003 Aug;42:2s-9s [12945994.001]

[Cites] Respir Physiol Neurobiol. 2004 Jan 15;139(2):167-77 [15123000.001]

[Cites] Anesthesiology. 2004 Sep;101(3):722-8 [15329597.001]

[Cites] Minerva Pediatr. 2004 Aug;56(4):373-80 [15457135.001]

[Cites] JAMA. 1986 Aug 15;256(7):881-6 [3090285.001]

[Cites] Am J Respir Crit Care Med. 1998 Jan;157(1):294-323 [9445314.001]

[Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47 [9563759.001]

[Cites] J Pharmacol Toxicol Methods. 1998 Aug;40(2):101-7 [10100499.001]

[Cites] Clin Chest Med. 2006 Dec;27(4):601-13; abstract viii [17085249.001]

[Cites] Clin Physiol Funct Imaging. 2007 Mar;27(2):67-90 [17309528.001]

[Cites] J Pediatr. 2007 Jul;151(1):10-5 [17586183.001]

[Cites] Neonatology. 2007;92(1):19-25 [17596733.001]

[Cites] Intensive Care Med. 2007 Aug;33(8):1423-33 [17563879.001]

[Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):575-81 [17641159.001]

[Cites] Crit Care Med. 2008 Jan;36(1):183-7 [18090370.001]

[Cites] Int J Mol Med. 2008 Apr;21(4):513-9 [18360698.001]

[Cites] J Perinatol. 2008 May;28 Suppl 1:S47-56 [18446178.001]

[Cites] Ann Thorac Surg. 2008 Aug;86(2):410-7; discussion 417 [18640306.001]

[Cites] BMC Pulm Med. 2008;8:10 [18625067.001]

[Cites] J Pediatr Surg. 1992 Jan;27(1):40-3 [1552442.001]

(PMID = 19687779.001).

[ISSN] 1530-0447

[Journal-full-title] Pediatric research

[ISO-abbreviation] Pediatr. Res.

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / HD046513-02; United States / NICHD NIH HHS / HD / K08 HD046513; United States / NHLBI NIH HHS / HL / R01 HL092906; United States / NICHD NIH HHS / HD / K08 HD046513-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS149422; NLM/ PMC2796292

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury.

OBJECTIVES: To measure serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury (SCI) and to investigate possible correlations between these serum levels and various factors, such as body mass index (BMI), age, injury level, and duration of injury.

MAIN OUTCOME MEASURES: Serum levels of adiponectin, ghrelin, and leptin and BMI.

RESULTS: Serum leptin levels in subjects with SCI (mean, 7.0+/-0.5 mg/mL) [corrected] were significantly higher than those in able-bodied controls (mean, 4.7+/-0.6 mg/mL) [corrected] (P<.01).

The group with tetraplegia had higher serum leptin levels than the group with paraplegia, but this did not reach a statistically significant level (8.2+/-1.1 ng/mL vs 6.4+/-0.5 mg/mL [corrected] P=.097).

There were significant differences in serum leptin levels among the 3 groups by 1-way analysis of variance (P=.008).

Serum adiponectin levels in subjects with SCI (7.1+/-0.5 mg/mL) [corrected] were higher than those in able-bodied controls (5.6+/-0.5 mg/mL) [corrected] but this was not statistically significant (P=.08).

In contrast, serum levels of ghrelin in subjects with SCI (302.0+/-17.5 pg/mL) were similar to those in the controls (264.0+/-27.0 pg/mL) (P=.24).

Serum leptin levels correlated positively with BMI (SCI, r=.698, P<.001; controls, r=.782, P<.001), whereas serum adiponectin (SCI, r=-.527, P<.001; controls, r=-.315, P=.057) and ghrelin (SCI, r=-.368, P<.001; controls, r=-.447, P=.006) levels correlated negatively with the BMI in both subjects with SCI and controls.

CONCLUSIONS: Men with SCI have significantly higher serum leptin levels than able-bodied controls, and serum leptin levels correlated with the degree of neurologic deficit.

Men with SCI had a tendency toward higher serum adiponectin level than able-bodied controls.

Serum levels of ghrelin in men with SCI were similar to those of controls.

[MeSH-major] Leptin / blood. Peptide Hormones / blood. Spinal Cord Injuries / blood

MedlinePlus Health Information. consumer health - Spinal Cord Injuries.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Arch Phys Med Rehabil. 2007 May;88(5):688

(PMID = 16213239.001).

[ISSN] 0003-9993

[Journal-full-title] Archives of physical medicine and rehabilitation

[ISO-abbreviation] Arch Phys Med Rehabil

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Ghrelin; 0 / Leptin; 0 / Peptide Hormones

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

BACKGROUND: The course of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) partly depends on the mutational status of the variable region of immunoglobulin heavy chain genes (IgV(H)), which defines two subgroups of tumours: mutated and unmutated.

METHODS: 26 patients with CLL/SLL detected on BMB and with known IgV(H) mutational status were selected.

ZAP70 was determined by immunohistochemistry (IHC) comparing three antibodies from different sources (Upstate, Cell Signaling, Santa Cruz, California, USA) and two different methods (APAAP and EnVision(+)).

RESULTS: ZAP70 determination on BMB specimens turned out to be easily feasible with routine procedures with reagents from Upstate and Cell Signaling.

CONCLUSIONS: The study confirms the role of ZAP70 as a possible surrogate of mutational status and emphasises its application in routine diagnostics; it discloses a small subset of discordant cases (mutated/ZAP70 weakly positive) that clinically cluster with the more favourable forms.

[MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / metabolism

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]

[Cites] Am J Clin Pathol. 1996 Oct;106(4):457-61 [8853032.001]

[Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]

[Cites] Leuk Res. 2001 Nov;25(11):927-32 [11597727.001]

[Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]

[Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]

[Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]

[Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]

[Cites] Br J Haematol. 2002 Jan;116(1):142-50 [11841407.001]

[Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]

[Cites] Ann Hematol. 2002 Jun;81(6):299-303 [12107557.001]

[Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]

[Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]

[Cites] Eur J Haematol. 2003 Jan;70(1):53-9 [12631259.001]

[Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]

[Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]

[Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]

[Cites] Leuk Lymphoma. 2004 Mar;45(3):455-62 [15160906.001]

[Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]

[Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):69-72 [15325098.001]

[Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii [15325699.001]

[Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):807-26, viii [15325700.001]

[Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):827-48, viii [15325701.001]

[Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]

[Cites] Leuk Lymphoma. 2004 Oct;45(10):2037-45 [15370248.001]

[Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]

[Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]

[Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]

[Cites] Br J Haematol. 1999 May;105(2):394-401 [10233410.001]

[Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]

[Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]

[Cites] J Pathol. 2005 Mar;205(4):507-13 [15685592.001]

[Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]

[Cites] Leukemia. 2005 May;19(5):750-8 [15759031.001]

[Cites] Leukemia. 2005 Jun;19(6):1018-24 [15800671.001]

[Cites] Cell. 1992 Nov 13;71(4):649-62 [1423621.001]

[Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]

[Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]

(PMID = 16916999.001).

[ISSN] 0021-9746

[Journal-full-title] Journal of clinical pathology

[ISO-abbreviation] J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase

[Other-IDs] NLM/ PMC1955054

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin levels, hormone levels, and hot flashes in midlife women.

OBJECTIVE: To examine the associations between serum leptin levels, sex steroid hormone levels, and hot flashes in normal weight and obese midlife women.

MAIN OUTCOME MEASURE(S): Serum leptin and sex steroid hormone levels.

RESULT(S): Correlation and regression models were performed to examine associations between leptin levels, hormone levels, and hot flashes.

Leptin levels were associated with BMI, with "ever experiencing hot flashes" (questionnaire), with hot flashes within the last 30 days, and with duration of hot flashes (>1 year, P=.03).

Leptin was positively correlated with testosterone, free testosterone index, and free estrogen index and inversely associated with levels of sex hormone-binding globulin.

In women with a body mass index>or=30 kg/m2, leptin levels no longer correlated with testosterone levels.

CONCLUSION(S): Serum leptin levels are associated with the occurrence and duration of hot flashes in midlife women; however, no correlation was found between leptin and serum estradiol.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

[Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2354-8 [7629229.001]

[Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):772-80 [8456878.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Maturitas. 1996 Apr;23(3):301-5 [8794424.001]

[Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):318-21 [8989281.001]

[Cites] Endocrinology. 1997 Feb;138(2):847-50 [9003026.001]

[Cites] Br J Obstet Gynaecol. 1997 Aug;104(8):923-33 [9255084.001]

[Cites] Endocrinology. 1998 Feb;139(2):551-8 [9449624.001]

[Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]

[Cites] Clin Exp Obstet Gynecol. 1997;24(3):163-6 [9478308.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2541-6 [9482922.001]

[Cites] Menopause. 1998 Spring;5(1):43-51 [9689194.001]

[Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):428-34 [10022396.001]

[Cites] Ginekol Pol. 1999 Jan;70(1):1-7 [10349800.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52 [10359836.001]

[Cites] Endocrine. 1999 Feb;10(1):19-23 [10403567.001]

[Cites] Semin Reprod Med. 2005 May;23(2):117-25 [15852197.001]

[Cites] Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E166-71 [15741239.001]

[Cites] Am J Obstet Gynecol. 2005 Aug;193(2):347-51 [16098853.001]

[Cites] Am J Obstet Gynecol. 2005 Oct;193(4):1353-60 [16202725.001]

[Cites] Alcohol Alcohol. 2005 Nov-Dec;40(6):563-8 [16087658.001]

[Cites] Maturitas. 2006 Jan 20;53(2):217-25 [15913927.001]

[Cites] Maturitas. 2006 Jan 20;53(2):133-43 [16368467.001]

[Cites] Obstet Gynecol. 1994 Jul;84(1):29-34 [8008318.001]

[Cites] Maturitas. 2006 Jun 20;54(3):260-9 [16423474.001]

[Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31 [16817831.001]

[Cites] Climacteric. 2007 Feb;10(1):27-37 [17364602.001]

[Cites] Fertil Steril. 2007 Jun;87(6):1483-6 [17276432.001]

[Cites] Obesity (Silver Spring). 2007 Sep;15(9):2217-24 [17890489.001]

[Cites] Am J Epidemiol. 2008 Jan 1;167(1):78-85 [17881385.001]

[Cites] Maturitas. 2008 Feb 20;59(2):149-57 [18280066.001]

[Cites] Fertil Steril. 2008 Oct;90(4):1161-8 [18304548.001]

[Cites] Int J Biometeorol. 1999 Nov;43(3):99-109 [10639901.001]

[Cites] J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):67-76 [11224946.001]

[Cites] Am J Hum Biol. 2001 Jul-Aug;13(4):453-64 [11400216.001]

[Cites] Obstet Gynecol. 2001 Sep;98(3):391-7 [11530118.001]

[Cites] Maturitas. 2002 Jan 30;41(1):69-77 [11809345.001]

[Cites] J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1417-29 [11837495.001]

[Cites] Atherosclerosis. 2002 Apr;161(2):455-62 [11888531.001]

[Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7 [12364429.001]

[Cites] Obstet Gynecol. 2003 Feb;101(2):264-72 [12576249.001]

[Cites] Am J Epidemiol. 2004 Jun 15;159(12):1189-99 [15191936.001]

[Cites] Endocrinology. 2004 Jul;145(7):3115-21 [15059958.001]

[Cites] J Gen Intern Med. 2004 Jul;19(7):740-6 [15209587.001]

[Cites] Clin Endocrinol (Oxf). 1985 Mar;22(3):293-312 [3884189.001]

[Cites] Ann Clin Biochem. 1985 Sep;22 ( Pt 5):489-97 [4062218.001]

[Cites] J Clin Endocrinol Metab. 1987 Apr;64(4):723-9 [3818901.001]

[Cites] Int J Obes. 1989;13(1):1-9 [2703288.001]

[Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]

[Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]

(PMID = 19476935.001).

[ISSN] 1556-5653

[Journal-full-title] Fertility and sterility

[ISO-abbreviation] Fertil. Steril.

[Language] ENG

[Grant] United States / NIA NIH HHS / AG / R01 AG018400-02; United States / NIA NIH HHS / AG / AG18400; United States / NIA NIH HHS / AG / R01 AG018400-03; United States / NIA NIH HHS / AG / R01 AG018400-05A2; United States / NIA NIH HHS / AG / R01 AG018400-01A1; United States / NIA NIH HHS / AG / R01 AG018400-06; United States / NIA NIH HHS / AG / R01 AG018400; United States / NIA NIH HHS / AG / R01 AG018400-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Leptin

[Other-IDs] NLM/ NIHMS109122; NLM/ PMC3939020

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does leptin predict incident hypertension in older adults?

OBJECTIVE: Leptin is associated with blood pressure (BP) in experimental and cross-sectional studies, but only one previous prospective study of middle-aged men has reported the association between leptin and incident hypertension.

We examined the association of leptin levels with incident hypertension in a population-based study of older men and women.

POPULATION: Participants were 602 community-dwelling older adults with normal baseline BP levels who attended a research clinic visit between 1984 and 1987 and again 4.4 years later (mean age was 66.2 +/- 11.4; 60.6% were men; mean body mass index (BMI) 24.9 +/- 3.4 kg/m(2)).

Leptin was measured by radioimmunoassay.

Baseline serum leptin levels were higher in participants who developed hypertension compared to persistent normotensives [median (25th-75th range)] [8.8(5-16) vs 7(4-11) ng/ml, P = 0.002].

In logistic regression models, leptin (log-transformed) predicted incident hypertension before and after adjustments for baseline age, BMI, systolic BP, total cholesterol, medications, and previous cardiovascular disease (OR 1.75 95% CI 1.17-2.61, P = 0.006).

CONCLUSION: Higher leptin levels were independently associated with increased odds of incident hypertension in older adults.

MedlinePlus Health Information. consumer health - High Blood Pressure.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hypertension. 2009 Mar;53(3):473-9 [19204185.001]

[Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3922-6 [18682500.001]

[Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44 [19174500.001]

[Cites] Am J Hypertens. 2009 May;22(5):577-80 [19229195.001]

[Cites] Hypertension. 2009 Jun;53(6):965-72 [19398660.001]

[Cites] J Vasc Res. 2009;46(6):609-17 [19571581.001]

[Cites] Diabetes Care. 2000 Jan;23(1):57-63 [10857969.001]

[Cites] Hypertens Res. 2000 Jul;23(4):303-10 [10912765.001]

[Cites] Int J Obes Relat Metab Disord. 2001 Jan;25(1):121-5 [11244467.001]

[Cites] Metabolism. 2001 Mar;50(3):325-9 [11230786.001]

[Cites] Clin Exp Hypertens. 2001 May;23(4):357-68 [11349826.001]

[Cites] J Neuroendocrinol. 2001 Oct;13(10):913-21 [11679060.001]

[Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]

[Cites] Obes Res. 2003 Jan;11(1):160-6 [12529499.001]

[Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]

[Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]

[Cites] Nephron. 1976;16(1):31-41 [1244564.001]

[Cites] Prev Med. 1976 Jun;5(2):207-15 [935073.001]

[Cites] Am J Epidemiol. 1980 Jun;111(6):705-12 [7386445.001]

[Cites] Hypertension. 1997 Sep;30(3 Pt 2):619-23 [9322991.001]

[Cites] Hypertension. 1998 Jan;31(1 Pt 2):409-14 [9453337.001]

[Cites] Eur J Pharmacol. 2005 Aug 22;518(2-3):175-81 [16054621.001]

[Cites] J Hypertens. 2006 May;24(5):789-801 [16612235.001]

[Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):532-41 [17118991.001]

[Cites] Am J Clin Nutr. 2009 Mar;89(3):991S-997S [19176740.001]

(PMID = 20148909.001).

[ISSN] 1365-2265

[Journal-full-title] Clinical endocrinology

[ISO-abbreviation] Clin. Endocrinol. (Oxf)

[Language] ENG

[Grant] United States / NIA NIH HHS / AG / AG028507-03; United States / NIDDK NIH HHS / DK / R01 DK031801-15; United States / NIA NIH HHS / AG / R01 AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-13S1; United States / NIA NIH HHS / AG / AG007181-13S1; United States / NIA NIH HHS / AG / R01 AG028507-02; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIA NIH HHS / AG / AG07181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NIA NIH HHS / AG / AG007181-13; United States / NIA NIH HHS / AG / R01 AG007181-13; United States / NIDDK NIH HHS / DK / R01 DK031801-16; United States / NIDDK NIH HHS / DK / DK31801; United States / NIA NIH HHS / AG / R01 AG028507-03; United States / NIA NIH HHS / AG / AG028507-02; United States / NIA NIH HHS / AG / AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-14; United States / NIA NIH HHS / AG / R37 AG007181; United States / NIA NIH HHS / AG / R01 AG028507; United States / NIA NIH HHS / AG / AG028507

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Leptin

[Other-IDs] NLM/ NIHMS175266; NLM/ PMC2891171

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.

OBJECTIVE: The adipocytokine leptin regulates weight centrally and participates in the regulation of the immune and inflammatory responses.

In the present study we investigated whether inflammation, obesity or both of these characteristics are potential determinants of circulating leptin concentrations in a group of RA patients on periodical treatment with the TNF-alpha-blocker-infliximab due to severe disease.

We also assessed whether the infusion of infliximab may alter circulating leptin concentrations in patients with severe RA.

Serum leptin levels were determined immediately prior to and after infliximab infusion.

RESULTS: There was a positive correlation between body mass index of RA patients and baseline serum level of leptin (rho=0.665, p<0.001).

Apart from a significant correlation with VCAM-1 (rho=0.349, p=0.04), no significant correlations between baseline leptin levels and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP levels, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin or the cumulative prednisone dose at the time of the study were found.

Leptin levels did not change upon infliximab infusion (p=0.48).

CONCLUSION: In RA patients on TNF-alpha blocker treatment, circulating leptin levels are unrelated to disease activity but constitute a manifestation of adiposity.

The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by reduction in serum levels of leptin.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Leptin / blood. Obesity / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors

Genetic Alliance. consumer health - Arthritis.

Genetic Alliance. consumer health - Rheumatoid arthritis.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

Hazardous Substances Data Bank. Infliximab .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19473561.001).

[ISSN] 0392-856X

[Journal-full-title] Clinical and experimental rheumatology

[ISO-abbreviation] Clin. Exp. Rheumatol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In response to HFD, body weight, fat pad weights, adipocyte size, and serum leptin levels increased significantly more in SHR.1N than SHR.

Microarray gene expression profiles [Affymetrix, 15,923 genes and expressed sequence tags (ESTs)] showed that multiple genes of molecular pathways involved in lipogenesis were downregulated to a similar level in both strains, whereas genes involved in fatty acid oxidation and energy dissipation were upregulated less in SHR.1N than SHR.

MedlinePlus Health Information. consumer health - Dietary Fats.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hypertension. 2000 Jul;36(1):14-9 [10904006.001]

[Cites] Nature. 2008 Aug 21;454(7207):961-7 [18719582.001]

[Cites] Cell. 2001 Sep 7;106(5):563-73 [11551504.001]

[Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]

[Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]

[Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]

[Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]

[Cites] J Biol Chem. 2003 Apr 4;278(14):11888-96 [12529376.001]

[Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]

[Cites] Hypertension. 2003 May;41(5):1047-55 [12654711.001]

[Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]

[Cites] Physiol Rev. 2004 Jan;84(1):277-359 [14715917.001]

[Cites] Science. 2004 May 28;304(5675):1301-5 [15166374.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R112-9 [15001430.001]

[Cites] Nature. 2004 Sep 9;431(7005):200-5 [15306821.001]

[Cites] Cell. 1982 May;29(1):53-60 [7105184.001]

[Cites] Biochem J. 1988 Feb 1;249(3):765-9 [3355496.001]

[Cites] Mol Endocrinol. 1988 May;2(5):395-403 [2901666.001]

[Cites] J Hypertens. 1989 Mar;7(3):217-21 [2708818.001]

[Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]

[Cites] J Clin Invest. 1995 Jul;96(1):158-62 [7615786.001]

[Cites] J Clin Invest. 1995 Dec;96(6):2914-23 [8675663.001]

[Cites] Diabetes. 1997 Sep;46(9):1468-72 [9287048.001]

[Cites] Eur J Clin Invest. 1998 Jan;28(1):59-66 [9502188.001]

[Cites] J Clin Invest. 1998 Jul 15;102(2):412-20 [9664083.001]

[Cites] J Clin Invest. 2004 Dec;114(12):1752-61 [15599400.001]

[Cites] J Biol Chem. 2005 Apr 22;280(16):15493-6 [15746100.001]

[Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4 [15936931.001]

[Cites] Biol Cell. 2005 Jul;97(7):479-86 [15966863.001]

[Cites] FASEB J. 2005 Sep;19(11):1567-9 [16009704.001]

[Cites] Am J Hypertens. 2005 Oct;18(10):1271-5 [16202847.001]

[Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]

[Cites] Obes Res. 2005 Dec;13(12):2122-31 [16421346.001]

[Cites] Curr Opin Nephrol Hypertens. 2006 Mar;15(2):173-8 [16481885.001]

[Cites] Cell Metab. 2006 Mar;3(3):223-9 [16517409.001]

[Cites] Exp Hematol. 2006 Aug;34(8):1106-14 [16863918.001]

[Cites] Biochem J. 2006 Sep 1;398(2):153-68 [16898874.001]

[Cites] Nature. 2006 Dec 14;444(7121):847-53 [17167472.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6 [17360536.001]

[Cites] Int J Obes (Lond). 2007 Jun;31(6):1004-13 [17130847.001]

[Cites] J Lipid Res. 2007 Dec;48(12):2751-61 [17872589.001]

[Cites] FEBS Lett. 2008 Jan 9;582(1):117-31 [18037376.001]

[Cites] Mol Endocrinol. 2008 May;22(5):1023-31 [18202144.001]

[Cites] Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E356-67 [18492779.001]

[Cites] Curr Hypertens Rep. 1999 Feb-Mar;1(1):42-50 [10981041.001]

(PMID = 19383622.001).

[ISSN] 1531-2267

[Journal-full-title] Physiological genomics

[ISO-abbreviation] Physiol. Genomics

[Language] ENG

[Grant] United States / Howard Hughes Medical Institute / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin

[Other-IDs] NLM/ PMC2696153

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A 65-year-old male with peripheral neuropathy and small lymphocytic lymphoma presented with erythema and edema of the left foot.

[MeSH-major] Arthropathy, Neurogenic / diagnosis. Diagnostic Errors. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Osteoarticular / diagnosis. Tuberculosis, Osteoarticular / microbiology

[MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Drug Therapy, Combination. Foot Ulcer / drug therapy. Foot Ulcer / microbiology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male. Peripheral Nervous System Diseases / complications. Synovial Fluid / microbiology

Genetic Alliance. consumer health - Tuberculosis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16217986.001).

[ISSN] 0038-4348

[Journal-full-title] Southern medical journal

[ISO-abbreviation] South. Med. J.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antitubercular Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relationship between leptin level and oxidative status parameters in hemodialysis patients.

Both serum leptin level and oxidative stress are increased in hemodialysis (HD) patients.

In the present study, we aimed to investigate whether there is association between oxidative status and leptin level in HD patients.

Serum leptin level, total peroxide (TP) level, total antioxidant capacity (TAC), and oxidative stress index (OSI) were determined.

Serum leptin level, TP level, and OSI were significantly higher in HD patients than controls (all P < 0.001) while TAC was lower (P < 0.001).

In HD patients, serum leptin level was significantly correlated with TP level and OSI (r = 0.372, P < 0.001 and r = 0.409, P < 0.001, respectively).

The correlation of serum leptin level with TP level and OSI remained statistically significant after adjusting for age, gender, and body-fat percentage (r = 0.446, P < 0.001 and r = 0.463, P < 0.001, respectively).

Hyperleptinemia seems to be associated with increased oxidative stress in HD patients, and this association may provide better understanding about the disorders related to either elevated serum leptin levels and/or increased oxidative stress in HD patients.

[MeSH-major] Leptin / blood. Oxidative Stress. Renal Dialysis

MedlinePlus Health Information. consumer health - Dialysis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19178446.001).

[ISSN] 1525-1594

[Journal-full-title] Artificial organs

[ISO-abbreviation] Artif Organs

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antioxidants; 0 / Leptin; 0 / Peroxides

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].

BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.

Immunophenotyping will make diagnosis more precise through analyzing the origin and differentiation status of tumor, which is necessary for treatment and prognosis prediction.

This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).

METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.

RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.

In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.

Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.

Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.

CONCLUSION: Multiparameter FCM can not only provide data of cell lineage and differentiation status but also detect phenotypic aberrancies, which is helpful for minimal residual disease detecting.

[MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology

MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.

MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17430665.001).

[Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer

[ISO-abbreviation] Ai Zheng

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.

Since leptin was suggested to be involved in bone remodeling, its possible involvement in fracture formation/prevention was evaluated, by determination of serum leptin level in geriatric population with hip fracture, and evaluation the relationships with biochemical parameters of bone remodeling.

Serum leptin level of this total population distributed between 1 and 134ng/ml.

40% of patients were in the normal range of our laboratory (10-40ng/ml), 40% had decreased leptin level (<10ng/ml) and 20% had higher leptin level (>40ng/ml).

No correlation was detected between serum leptin level and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.

Leptin also did not correlate to ICTP level, which was high in 80% of the patients, suggesting an extensive bone resorption in this population.

Evaluation of leptin level in female versus male suggests that leptin level is higher in females than males also in this age (28.4ng/ml vs. 14.4ng/ml, p<0.001).

The higher leptin levels in women was accompanied by higher serum levels of glucose, albumin, Ca, cholesterol, Na and FT4.

Comparison of 50 patients with the lowest leptin levels (mean of 3.4ng/ml) to 50 patients with highest leptin levels (mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in leptin levels.

The high range of serum leptin concentration in these geriatric patients with hip fracture of both sexes, and the absence of any correlation between leptin and the tested parameters of bone resorption and Ca metabolism, teleopeptide type I collagen (ICTP) and 25(OH)D3, does not support a direct massive involvement of serum leptin in hip fracture of the very old population.

[MeSH-major] Bone Remodeling / physiology. Hip Fractures / blood. Leptin / blood

[MeSH-minor] Aged. Aged, 80 and over. Biomarkers / blood. Calcifediol / blood. Case-Control Studies. Cohort Studies. Collagen Type I. Dihydroxycholecalciferols / blood. Female. Humans. Male. Peptide Fragments / blood. Peptides. Procollagen / blood. Sex Distribution

MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18359113.001).

[ISSN] 1872-6976

[Journal-full-title] Archives of gerontology and geriatrics

[ISO-abbreviation] Arch Gerontol Geriatr

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Dihydroxycholecalciferols; 0 / Leptin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; P6YZ13C99Q / Calcifediol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epithelial-stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma.

In addition, this was associated with 2 synchronous malignant neoplasms, chromophobe renal cell carcinoma and small lymphocytic lymphoma, both of which were detected incidentally after clinical presentation because of the seminal vesicle mass.

[MeSH-major] Carcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Genital Neoplasms, Male / diagnosis. Kidney Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminal Vesicles

Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.

Genetic Alliance. consumer health - Renal cell carcinoma.

MedlinePlus Health Information. consumer health - Kidney Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18995209.001).

[ISSN] 1532-8198

[Journal-full-title] Annals of diagnostic pathology

[ISO-abbreviation] Ann Diagn Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 28

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

FACC1KO mice showed prenatal growth retardation; after weaning, however, their weight gain was comparable to that of wild-type (WT) mice on a normal diet.

In addition, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the serum leptin level was decreased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.

Fatty acid analyses of mutant bone lipids revealed relatively higher levels of C18:2n-6 and C18:3n-3 and lower levels of their elongation C20 homologs than that of WT cohorts, leading to lower levels of C20 homologs and bone development.

MedlinePlus Health Information. consumer health - Growth Disorders.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1964 Feb;239:375-80 [14169133.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]

[Cites] Expert Opin Ther Targets. 2005 Apr;9(2):267-81 [15934915.001]

[Cites] Cell Metab. 2005 Feb;1(2):107-19 [16054052.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12011-6 [16103361.001]

[Cites] Cell Mol Life Sci. 2005 Aug;62(16):1784-803 [15968460.001]

[Cites] Mol Cell Biol. 2006 Feb;26(3):1063-76 [16428458.001]

[Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8552-7 [16717184.001]

[Cites] J Bone Miner Res. 2006 Sep;21(9):1350-8 [16939393.001]

[Cites] Transgenic Res. 2006 Oct;15(5):647-53 [16952017.001]

[Cites] Endocrinology. 2006 Oct;147(10):4753-61 [16857753.001]

[Cites] Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7 [17234407.001]

[Cites] Gastroenterology. 2007 May;132(6):2103-15 [17498506.001]

[Cites] Cell. 2007 Aug 10;130(3):456-69 [17693256.001]

[Cites] Nat Med. 2008 Mar;14(3):299-305 [18297084.001]

[Cites] Cell. 2000 Jan 21;100(2):197-207 [10660043.001]

[Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]

[Cites] Endocr Rev. 2000 Aug;21(4):393-411 [10950158.001]

[Cites] Endocrinology. 2000 Dec;141(12):4436-41 [11108252.001]

[Cites] Dev Biol. 2001 Jan 1;229(1):141-62 [11133160.001]

[Cites] Prog Lipid Res. 2001 Jan-Mar;40(1-2):125-48 [11137570.001]

[Cites] Trends Endocrinol Metab. 2000 Oct;11(8):327-32 [10996528.001]

[Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]

[Cites] Biochem J. 2001 Aug 15;358(Pt 1):127-35 [11485560.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):138-43 [11756679.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7515-20 [12810950.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [14660788.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63 [14978271.001]

[Cites] Methods Enzymol. 1975;35:59-65 [235706.001]

[Cites] J Biol Chem. 1983 Sep 25;258(18):11074-81 [6136512.001]

[Cites] Annu Rev Biochem. 1983;52:537-79 [6137188.001]

[Cites] J Biol Chem. 1985 May 25;260(10):6318-23 [2860106.001]

[Cites] J Biol Chem. 1988 May 5;263(13):6447-53 [2896193.001]

[Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]

[Cites] Genes Dev. 1993 Dec;7(12B):2609-17 [8276243.001]

[Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]

[Cites] Gene. 1995 Mar 10;154(2):271-5 [7890176.001]

[Cites] Brain Res Dev Brain Res. 1997 Feb 20;98(2):197-203 [9051261.001]

[Cites] Annu Rev Nutr. 1997;17:77-99 [9240920.001]

[Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]

[Cites] Genes Dev. 1999 Apr 15;13(8):1025-36 [10215629.001]

[Cites] J Nutr Biochem. 2004 Nov;15(11):651-6 [15590268.001]

(PMID = 19805143.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM063115; United States / NIGMS NIH HHS / GM / GM-63115

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / aminoglycoside N1-acetyltransferase; EC 6.4.1.2 / Acetyl-CoA Carboxylase

[Other-IDs] NLM/ PMC2762677

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.

BACKGROUND: Solar radiation has been identified as a principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy.

No study has investigated the role of leptin, a hormone whose levels increase in obesity and which has also been related to cancer.

Anthropometrical measures were also recorded and blood samples were obtained for determination of serum leptin levels.

RESULTS: An excess melanoma risk was observed for sun sensitive individuals and those with high circulating levels of leptin (OR: 1.56, 95% confidence interval 1.07-2.28, P = 0.02), after controlling for obesity indices, diabetes mellitus and education.

CONCLUSIONS: Melanoma risk was found to be positively associated with serum leptin levels and inversely with healthy lifestyle factors.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17925285.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents.

OBJECTIVE: To investigate the relationship between serum leptin and lipid profile in South Indian School children and adolescents, and to evaluate the role of serum leptin in obese, overweight and congenital heart diseased children and adolescents; in South Indian population and its correlation with anthropometric and biochemical parameters.

Anthropometric variables, lipid profile, fasting serum glucose were analyzed by autoanalyser and serum leptin by ELISA.

RESULTS: Serum leptin levels were significantly elevated in obese and overweight children than in control children (36.88+/-18.60ng/mL, 20.64+/-11.18ng/mL vs 7.97+/-2.79ng/mL; p value <0.001), and decreased in congenital heart diseased children than in control children (6.20+/-4.23 ng/mL vs 7.97+/-2.79ng/mL; p value <0.005).

CONCLUSIONS: This study provides a good relationship between serum leptin levels and anthropometric and biochemical parameters, such as total cholesterol, triglycerides and LDL-cholesterol.

We observed negative correlation between serum leptin and fasting glucose levels and HDL-cholesterol levels were found to be non-significant among the groups.

Further studies with large sample size are needed to ascertain the relationship between serum leptin and lipid profile in different groups of children and adolescents.

[MeSH-major] Heart Defects, Congenital / blood. Leptin / blood. Lipids / blood. Obesity / blood. Overweight / blood

MedlinePlus Health Information. consumer health - Congenital Heart Defects.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Obesity in Children.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Invest. 1997 Aug 15;100(4):808-13 [9259579.001]

[Cites] J Clin Invest. 2000 May;105(9):1243-52 [10791999.001]

[Cites] Obes Res. 2003 Apr;11(4):532-40 [12690082.001]

[Cites] Eur J Clin Nutr. 2007 Jun;61(6):719-26 [17164827.001]

[Cites] Ann Intern Med. 1997 Jan 1;126(1):26-31 [8992920.001]

[Cites] Int J Cardiol. 2003 Nov;92(1):93-7 [14602223.001]

[Cites] Eur J Epidemiol. 2001;17(10):911-6 [12188009.001]

[Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]

[Cites] J Intern Med. 1999 Oct;246(4):409-18 [10583712.001]

[Cites] Obes Res. 2005 Aug;13(8):1476-84 [16129731.001]

[Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52 [9215286.001]

[Cites] Indian Pediatr. 2007 Apr;44(4):257-62 [17468520.001]

[Cites] Pediatrics. 2005 Apr;115(4):e500-3 [15741351.001]

[Cites] Indian J Pediatr. 2006 Jul;73(7):593-6 [16877853.001]

[Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]

(PMID = 20401706.001).

[ISSN] 0973-7693

[Journal-full-title] Indian journal of pediatrics

[ISO-abbreviation] Indian J Pediatr

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 0 / Lipids

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.

OBJECTIVE: To compare the changes in body composition and in leptin levels in postmenopausal women receiving hormone therapy (HT) or tibolone.

MAIN OUTCOME MEASURE(S): Anthropometric indices, leptin levels, tissue fat percentage, total fat, and lean mass measurements were performed at baseline and after 6 months.

RESULT(S): The serum leptin levels were in strong correlation with the total fat percentage and total fat mass at baseline.

Untreated women had weight gain and a gradual decrease in leptin levels.

Women receiving HT had significantly increased leptin levels.

Women in the tibolone group, however, had a significant decrease in leptin levels accompanied by decreased total fat mass, fat percentage, and increased total lean mass.

The changes in leptin levels were more pronounced in lean women.

CONCLUSION(S): Postmenopausal women tend to gain weight accompanied with a reduction in leptin concentrations.

Hormone therapy administration increases leptin levels while maintaining body weight and body fat distribution, whereas tibolone use decreases leptin levels, total fat percentage, and total fat mass.

[MeSH-major] Adiposity / drug effects. Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / therapeutic use. Leptin / blood. Medroxyprogesterone Acetate / therapeutic use. Norpregnenes / therapeutic use. Postmenopause. Weight Gain / drug effects

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18249383.001).

[ISSN] 1556-5653

[Journal-full-title] Fertility and sterility

[ISO-abbreviation] Fertil. Steril.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Estrogens, Conjugated (USP); 0 / Leptin; 0 / Norpregnenes; C2QI4IOI2G / Medroxyprogesterone Acetate; FF9X0205V2 / tibolone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells.

Serum leptin levels are often elevated in obese people.

Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated.

The purpose of this study is to investigate the proliferation and mobility effects in leptin-treated Caki-2 renal cell carcinoma and analyze the alterations of leptin-inducible STAT3 pathways and mitogenic signaling ERK pathways.

Our results indicate the constitutive expression of leptin receptor could not be upregulated upon the stimulation of leptin in Caki-2 cells.

Leptin increases the proliferation and mobility capabilities of Caki-2 cells via upregulating the expression of both phosphor-ERK and phosphor-STAT3 and these two pathways could be partially abolished by inhibition of the activation of JAK-STAT3 and completely abrogated by inhibition of ERK1/2 pathways.

Our results also suggest that mitogenic actions of leptin are not the consequence of altered its receptor expression; whereas the cellular proliferation appears to be working through the cross-talking of JAK-STAT3 and ERK1/2 pathways in renal cell carcinoma caki-2 cells.

[MeSH-major] Carcinoma, Renal Cell / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Janus Kinase 1 / metabolism. Leptin / metabolism. STAT3 Transcription Factor / metabolism

[MeSH-minor] Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Kidney Neoplasms / metabolism. MAP Kinase Signaling System. Obesity / metabolism. Protein Kinase C / metabolism. Signal Transduction

Genetic Alliance. consumer health - Renal cell carcinoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18787400.001).

[ISSN] 1555-8576

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin; 0 / STAT3 Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.

BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.

Serum leptin levels were within the range predicted by the elevated fat mass in these subjects.

Their clinical features were less severe than those of subjects with congenital leptin deficiency.

Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency.

Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.

[MeSH-major] Metabolism, Inborn Errors / diagnosis. Metabolism, Inborn Errors / genetics. Obesity / genetics. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics

[MeSH-minor] Adult. Age of Onset. Basal Metabolism. Body Composition. Child. Diagnosis, Differential. Female. Genotype. Humans. Hyperphagia / blood. Hyperphagia / complications. Hyperphagia / genetics. Hypogonadism / blood. Hypogonadism / complications. Hypogonadism / genetics. Immunologic Deficiency Syndromes / blood. Immunologic Deficiency Syndromes / complications. Immunologic Deficiency Syndromes / genetics. Leptin / blood. Lymphocyte Count. Male. Mutation. Pedigree. Phenotype. Receptors, Leptin

Genetic Alliance. consumer health - Leptin receptor deficiency.

Genetics Home Reference. consumer health - leptin receptor deficiency.

Genetics Home Reference. consumer health - LEPR gene.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Obesity in Children.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

SciCrunch. OMIM: Data: Gene Annotation .

SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2007 Massachusetts Medical Society.

[Cites] Diabetes. 2000 Aug;49(8):1347-52 [10923636.001]

[Cites] Clin Endocrinol (Oxf). 2006 Jun;64(6):667-71 [16712669.001]

[Cites] Int J Obes Relat Metab Disord. 2002 May;26(5):640-6 [12032747.001]

[Cites] Obes Rev. 2001 Feb;2(1):29-36 [12119634.001]

[Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]

[Cites] N Engl J Med. 2003 Mar 20;348(12):1085-95 [12646665.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]

[Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6 [15472169.001]

[Cites] Am J Clin Nutr. 1979 Mar;32(3):607-29 [420153.001]

[Cites] Am J Clin Nutr. 1982 May;35(5 Suppl):1169-75 [7081099.001]

[Cites] Am J Clin Nutr. 1991 Dec;54(6):963-9 [1957828.001]

[Cites] Eur J Clin Nutr. 1993 Oct;47(10):724-34 [8269887.001]

[Cites] Diabet Med. 1995 Jan;12(1):30-5 [7712700.001]

[Cites] Arch Dis Child. 1995 Jul;73(1):25-9 [7639544.001]

[Cites] J Pediatr. 1995 Oct;127(4):571-7 [7562278.001]

[Cites] Biochem Biophys Res Commun. 1997 Apr 7;233(1):248-52 [9144432.001]

[Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]

[Cites] Nat Genet. 1997 Jul;16(3):303-6 [9207799.001]

[Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]

[Cites] Nature. 1998 Mar 26;392(6674):398-401 [9537324.001]

[Cites] Am J Physiol. 1998 Apr;274(4 Pt 2):R985-90 [9575960.001]

[Cites] Nat Genet. 1998 Jun;19(2):155-7 [9620771.001]

[Cites] Nature. 1998 Aug 27;394(6696):897-901 [9732873.001]

[Cites] Baillieres Clin Endocrinol Metab. 1998 Jul;12(2):297-314 [10083898.001]

[Cites] N Engl J Med. 1999 Sep 16;341(12):879-84 [10486419.001]

[Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3686-95 [10523015.001]

[Cites] Annu Rev Med. 2005;56:443-58 [15660521.001]

[Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1849-55 [15598687.001]

[Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1871-87 [15598688.001]

[Cites] Nature. 2001 Nov 1;414(6859):34-5 [11689931.001]

(PMID = 17229951.001).

[ISSN] 1533-4406

[Journal-full-title] The New England journal of medicine

[ISO-abbreviation] N. Engl. J. Med.

[Language] eng

[Grant] Italy / Telethon / / GJT04008; United Kingdom / Wellcome Trust / / 077016; United Kingdom / Wellcome Trust / / 068086; United Kingdom / Medical Research Council / / G0502115; United Kingdom / Wellcome Trust / / 067457; United Kingdom / Wellcome Trust / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human

[Other-IDs] NLM/ PMC2670197; NLM/ UKMS4351

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.

We used recombinant adeno-associated virus (rAAV)-mediated gene delivery to overexpress a mutant of rat leptin yielding a protein that acts as a neutral leptin receptor antagonist.

Leptin antagonist overexpression was confirmed by examination of mRNA levels in the hypothalamus.

The degree of antagonist overexpression was sufficient to partially block signal transducer and activator of transcription 3 (STAT3) phosphorylation due to administration of an acute submaximal dose of leptin.

In contrast, when leptin was overexpressed in the hypothalamus, WR activity was increased by greater than twofold.

At death, adiposity and serum leptin levels were greater in the antagonist group.

These data indicate that submaximal central leptin receptor blockade promotes obesity and diminishes WR activity.

These findings underscore the critical role of unrestrained leptin receptor activity in long-term energy homeostasis and suggest that even minor disruption of leptin receptor function can promote obesity.

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2000 Apr 6;404(6778):661-71 [10766253.001]

[Cites] J Clin Invest. 1995 Sep;96(3):1658-63 [7657836.001]

[Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]

[Cites] Regul Pept. 2001 Jun 15;99(2-3):69-77 [11384767.001]

[Cites] Neuroscience. 2001;104(4):1111-7 [11457594.001]

[Cites] Neuropharmacology. 2002 Mar;42(4):548-61 [11955525.001]

[Cites] Obes Rev. 2000 Oct;1(2):87-94 [12119990.001]

[Cites] Endocrinology. 2002 Aug;143(8):3026-35 [12130569.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83 [9238071.001]

[Cites] Am J Physiol. 1997 Jul;273(1 Pt 1):E226-30 [9252501.001]

[Cites] Diabetes. 1997 Nov;46(11):1782-5 [9356026.001]

[Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]

[Cites] Endocrinology. 1998 Sep;139(9):3681-90 [9724018.001]

[Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]

[Cites] J Biol Chem. 1999 Jun 18;274(25):17541-4 [10364187.001]

[Cites] Nat Biotechnol. 2004 Dec;22(12):1583-7 [15568020.001]

[Cites] Diabetologia. 2005 Jun;48(6):1075-83 [15864530.001]

[Cites] J Virol. 2006 Feb;80(4):1874-85 [16439543.001]

[Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):706-12 [17082312.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R868-74 [17023670.001]

[Cites] Front Biosci. 2007;12:3531-44 [17485319.001]

[Cites] Behav Brain Res. 2008 Mar 17;188(1):100-8 [18063139.001]

[Cites] Diabetes. 2008 Mar;57(3):614-22 [18086903.001]

[Cites] Endocrinology. 2008 Jun;149(6):3009-15 [18308842.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1370-5 [18703413.001]

[Cites] Exp Biol Med (Maywood). 2002 Sep;227(8):587-600 [12192100.001]

[Cites] Methods. 2002 Oct;28(2):158-67 [12413414.001]

[Cites] Expert Opin Investig Drugs. 2003 Mar;12(3):373-8 [12605561.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1011-20 [14557234.001]

[Cites] Obes Res. 2004 Jan;12(1):150-60 [14742854.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]

[Cites] Metabolism. 1977 Apr;26(4):371-80 [846405.001]

[Cites] Q J Exp Physiol. 1987 Oct;72(4):549-59 [3423201.001]

[Cites] Science. 1995 Jul 28;269(5223):543-6 [7624777.001]

[Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]

[Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]

(PMID = 19726711.001).

[ISSN] 1522-1490

[Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology

[ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.

[Language] ENG

[Grant] United States / NIA NIH HHS / AG / AG-26159; United States / NIA NIH HHS / AG / P30-AG-028740,

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Ion Channels; 0 / Leptin; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / Receptors, Leptin; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / mitochondrial uncoupling protein

[Other-IDs] NLM/ PMC2777784

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles.

OBJECTIVE: The aim of this study was to evaluate leptin and adiponectin blood levels in women with premature ovarian failure (POF) and women with a normal menstrual cycle.

Serum leptin levels were significantly lower in G1 compared with G2 (8.8 +/- 12.2 and 12.2 +/- 9.7 ng/mL; P < 0.05).

Serum adiponectin levels were similar in both groups.

Leptin levels were positively correlated to weight (r = 0.38; P = 0.03) but were not correlated to BMI and age in women with POF (G1); in G2, they were positively correlated to BMI (r = 0.59; P = 0.0006), weight (r = 0.63; P = 0.0006), and age (r = 0.40; P = 0.02).

Adiponectin levels did not correlate to weight, BMI, or age in both groups.

CONCLUSIONS: These results suggest that gonadal function loss may decrease leptin circulating levels, independently from age and BMI.

[MeSH-major] Adiponectin / blood. Leptin / blood. Primary Ovarian Insufficiency / blood

Genetic Alliance. consumer health - premature ovarian failure.

MedlinePlus Health Information. consumer health - Premature Ovarian Failure.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19609224.001).

[ISSN] 1530-0374

[Journal-full-title] Menopause (New York, N.Y.)

[ISO-abbreviation] Menopause

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adiponectin; 0 / Leptin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice.

RESULTS: In fetuses whose mothers consumed the low-phytoestrogen PMI 5K96 feed, we found a paradoxical significant elevation in endogenous serum estradiol, which was associated postnatally with adverse reproductive outcomes referred to as the "fetal estrogenization syndrome (FES)".

The low-phytoestrogen-fed males and females were lighter at birth, but, between weaning and adulthood, they became obese and developed abnormally high serum leptin levels; these males, but not females, showed impaired glucose regulation.

Genetic Alliance. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Obesity.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ESTRADIOL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61 [9050904.001]

[Cites] Environ Health Perspect. 2003 Jun;111(8):994-1006 [12826473.001]

[Cites] Toxicol Ind Health. 1998 Jan-Apr;14(1-2):239-60 [9460178.001]

[Cites] Environ Health Perspect. 1998 Jul;106(7):369-73 [9637793.001]

[Cites] Epidemiol Rev. 1998;20(2):157-72 [9919436.001]

[Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1127-35 [15564439.001]

[Cites] J Nutr. 2005 May;135(5):1331-5 [15867335.001]

[Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):7014-9 [15867144.001]

[Cites] Birth Defects Res A Clin Mol Teratol. 2005 Jul;73(7):478-80 [15959888.001]

[Cites] Environ Res. 2006 Jan;100(1):50-76 [16256977.001]

[Cites] Reprod Toxicol. 2006 Apr;21(3):307-12 [16257506.001]

[Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]

[Cites] Lab Anim. 2007 Jan;41(1):1-18 [17234046.001]

[Cites] Environ Health Perspect. 2007 Jun;115(6):902-8 [17589598.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-61 [17670942.001]

[Cites] Environ Health Perspect. 2007 Oct;115(10):1467-73 [17938737.001]

[Cites] Environ Health Perspect. 2008 Mar;116(3):389-93 [18335108.001]

[Cites] Nature. 1999 Oct 21;401(6755):763-4 [10548101.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34 [11070086.001]

[Cites] J Nutr. 2001 Feb;131(2):354S-60S [11160560.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]

[Cites] Exp Biol Med (Maywood). 2001 Dec;226(11):978-81 [11743132.001]

[Cites] Comp Med. 2003 Dec;53(6):607-15 [14727808.001]

[Cites] Reprod Toxicol. 2004 May;18(3):399-406 [15082075.001]

[Cites] J Anim Sci. 1989 Jul;67(7):1824-40 [2670873.001]

[Cites] Biol Reprod. 1990 Nov;43(5):751-61 [2291911.001]

[Cites] J Vet Diagn Invest. 1990 Oct;2(4):268-73 [2151311.001]

[Cites] Endocrinology. 1992 Jun;130(6):3184-90 [1375894.001]

[Cites] Biol Reprod. 1992 Nov;47(5):723-9 [1477199.001]

[Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]

[Cites] Biol Reprod. 1995 Nov;53(5):1198-207 [8527526.001]

[Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:83-7 [8593881.001]

[Cites] Clin Chem. 1996 Jun;42(6 Pt 1):955-64 [8665689.001]

[Cites] Med Sci Monit. 2002 Dec;8(12):RA282-92 [12503048.001]

[Cites] Clin Chem. 1997 May;43(5):850; author reply 852 [9166244.001]

(PMID = 18335098.001).

[ISSN] 0091-6765

[Journal-full-title] Environmental health perspectives

[ISO-abbreviation] Environ. Health Perspect.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / R01 ES011283; United States / NIGMS NIH HHS / GM / T32 GM008396; United States / NIEHS NIH HHS / ES / ES11283

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin; 0 / Phytoestrogens; 4TI98Z838E / Estradiol

[Other-IDs] NLM/ PMC2265041

[Keywords] NOTNLM ; casein / estradiol / fat / glucose tolerance / leptin / metabolic syndrome / obesity / puberty / reproductive organs / soy

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This effect was accompanied by decreased serum leptin levels in CLA-fed and CLA + Cr-fed mice, and by higher energy expenditure (EE) and oxygen consumption (OC) in CLA + Cr-fed mice.

Serum levels of glucose, insulin, the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), as well as insulin resistance index (IRI), decreased with CLA, whereas CLA and Cr in combination had significant effects on insulin and IL-6 concentrations and IRI.

In summary, CLA + Cr decreased body weight and fat mass in high-fat-diet-fed mice, which may be associated with decreased leptin levels and higher EE and OC.

[MeSH-minor] Adiponectin / blood. Analysis of Variance. Animals. Dietary Fats / administration & dosage. Dietary Fats / pharmacology. Energy Metabolism / drug effects. Leptin / blood. Male. Mice. Mice, Inbred BALB C

MedlinePlus Health Information. consumer health - Body Weight.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Obes Rev. 2005 Aug;6(3):247-58 [16045640.001]

[Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):679-84 [15369804.001]

[Cites] Diabetes. 2000 Sep;49(9):1534-42 [10969838.001]

[Cites] Am J Clin Nutr. 2004 Oct;80(4):887-95 [15447895.001]

[Cites] Diabetes Res Clin Pract. 1996 Mar;31(1-3):27-35 [8792099.001]

[Cites] Lipids Health Dis. 2005 Jan 10;4:3 [15642120.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1199S-1206S [15159257.001]

[Cites] Biosci Biotechnol Biochem. 2002 Apr;66(4):916-20 [12036077.001]

[Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]

[Cites] Int J Obes Relat Metab Disord. 2003 Apr;27(4):522-9 [12664086.001]

[Cites] J Nutr Biochem. 2004 Nov;15(11):680-7 [15590272.001]

[Cites] Wei Sheng Yan Jiu. 2000 Nov;29(6):370-1 [12520958.001]

[Cites] J Biomed Mater Res. 1996 Dec;32(4):655-61 [8953156.001]

[Cites] Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99 [12020636.001]

[Cites] J Lipid Res. 2002 Sep;43(9):1400-9 [12235171.001]

[Cites] J Endocrinol. 1998 Oct;159(1):165-72 [9795354.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6):1118-25 [15159244.001]

[Cites] Aging (Milano). 1997 Feb-Apr;9(1-2):73-9 [9177588.001]

[Cites] Nutr Rev. 1998 Sep;56(9):266-70 [9763876.001]

[Cites] J Nutr. 2005 May;135(5):1124-30 [15867292.001]

[Cites] Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):67-79 [15772897.001]

[Cites] Metabolism. 1998 Apr;47(4):396-400 [9550535.001]

[Cites] Diabetologia. 2004 Jun;47(6):1016-9 [15168020.001]

[Cites] Am J Physiol. 1998 Sep;275(3 Pt 2):R667-72 [9728060.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1153S-1158S [15159250.001]

[Cites] Diabetes Care. 2002 Sep;25(9):1516-21 [12196420.001]

[Cites] J Nutr Sci Vitaminol (Tokyo). 2004 Dec;50(6):416-21 [15895517.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1169S-1174S [15159253.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1164S-1168S [15159252.001]

[Cites] Lipids. 2002 Jul;37(7):725-8 [12216844.001]

[Cites] Diabetes. 2002 Jul;51(7):2037-44 [12086931.001]

[Cites] Annu Rev Nutr. 2002;22:505-31 [12055356.001]

[Cites] J Bone Miner Res. 2003 Jul;18(7):1206-16 [12854830.001]

[Cites] J Dairy Sci. 1995 Nov;78(11):2358-65 [8747326.001]

[Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]

[Cites] Diabetes Obes Metab. 2001 Aug;3 Suppl 1:S11-9 [11685824.001]

[Cites] Biochem Biophys Res Commun. 2003 Apr 11;303(3):795-9 [12670481.001]

[Cites] Lipids. 1997 Aug;32(8):853-8 [9270977.001]

[Cites] Prog Lipid Res. 2004 Nov;43(6):553-87 [15522764.001]

[Cites] J Am Coll Nutr. 2005 Jun;24(3):200-9 [15930486.001]

[Cites] Public Health Nutr. 2004 Feb;7(1A):123-46 [14972057.001]

[Cites] Lipids. 2001 Jul;36(7):669-74 [11521964.001]

[Cites] Nutrition. 1999 Sep;15(9):720-2 [10467621.001]

[Cites] J Biol Chem. 2005 Nov 18;280(46):38445-56 [16155293.001]

[Cites] JAMA. 1999 Oct 27;282(16):1519-22 [10546690.001]

[Cites] Nature. 2000 Apr 6;404(6778):635-43 [10766250.001]

[Cites] Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E527-33 [12736161.001]

[Cites] J Nutr. 2003 Jun;133(6):1793-9 [12771319.001]

[Cites] Diabetes Res Clin Pract. 1995 Jun;28(3):179-84 [8529496.001]

[Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71 [15181039.001]

[Cites] J Nutr. 2000 Oct;130(10 ):2471-7 [11015475.001]

[Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1132S-1136S [15159246.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2057-65 [11080069.001]

[Cites] Am J Clin Nutr. 1985 May;41(5 Suppl):1132-45 [3993620.001]

[Cites] J Nutr. 2002 Oct;132(10):2995-8 [12368384.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):860-1 [10622250.001]

[Cites] Diabetes. 2001 May;50(5):1149-57 [11334420.001]

[Cites] Nutrition. 2003 Jan;19(1):30-5 [12507636.001]

[Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E563-9 [10710512.001]

[Cites] Am J Clin Nutr. 1981 Dec;34(12):2670-8 [7032273.001]

[Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):562-6 [14521947.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6207-12 [15833818.001]

[Cites] Am J Vet Res. 1997 Jun;58(6):594-600 [9185964.001]

[Cites] Int J Obes. 1991 Sep;15 Suppl 2:109-15 [1794931.001]

[Cites] Obes Res. 2003 Mar;11(3):368-72 [12634431.001]

[Cites] J Nutr. 2005 Apr;135(4):778-84 [15795434.001]

[Cites] Metabolism. 1992 Jul;41(7):768-71 [1619996.001]

[Cites] Diabetes Care. 1994 Dec;17(12):1449-52 [7882815.001]

[Cites] Diabet Med. 2000 Sep;17(9):684-5 [11051290.001]

[Cites] Nutrition. 2004 Nov-Dec;20(11-12):1008-17 [15561492.001]

[Cites] Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82 [9535724.001]

[Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]

[Cites] Lipids. 1999 Mar;34(3):235-41 [10230716.001]

(PMID = 16933788.001).

[ISSN] 0024-4201

[Journal-full-title] Lipids

[ISO-abbreviation] Lipids

[Language] eng

[Grant] United States / NIA NIH HHS / AG / AG023648; United States / NIA NIH HHS / AG / AG027562

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Adiponectin; 0 / Dietary Fats; 0 / Leptin; 0 / Linoleic Acids, Conjugated; 0R0008Q3JB / Chromium

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis.

OBJECTIVE: To ascertain the relationship between serum leptin levels and related variables (weight, Body Mass Index (BMI) and fat percentage) in a group of Omani obese and non-obese healthy subjects.

METHODS: Leptin levels were assessed in serum samples from 35 obese Omanis and 20 non-obese healthy subjects.

RESULTS: There was a significant difference (p< 0.001) in serum leptin between the obese group (34.78 + 13.96 ng/ml) and the control non-obese subjects (10.6 ± 4.2 ng/ml).

Leptin levels were higher in females compared to males.

There was a significantly positive correlation between leptin levels in obese subjects with weight (p=0.002), body fat percentage (p=0.0001) and BMI (p=0.001).

CONCLUSIONS: We concluded that serum leptin levels are higher in the Omani obese group and correlate positively with body fatness and obesity.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]

[Cites] J Clin Endocrinol Metab. 1997 May;82(5):1632-4 [9141562.001]

[Cites] J Clin Invest. 1997 May 15;99(10):2398-404 [9153282.001]

[Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4144-8 [9398729.001]

[Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2149-55 [9626154.001]

[Cites] Kidney Int. 1998 Oct;54(4):1267-75 [9767543.001]

[Cites] Horm Res. 1998;50(6):297-302 [9973668.001]

[Cites] Adv Physiol Educ. 2003 Dec;27(1-4):70-7 [12760843.001]

[Cites] Diabet Med. 2002 Nov;19(11):954-7 [12421434.001]

[Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23 [8784108.001]

[Cites] Ann Saudi Med. 2000 Mar;20(2):113-8 [17322705.001]

[Cites] Diabetes. 2002 Jun;51(6):1980-5 [12031989.001]

[Cites] Physiol Res. 2001;50(5):443-59 [11702849.001]

[Cites] Atherosclerosis. 2001 Aug;157(2):495-503 [11472752.001]

[Cites] Cesk Fysiol. 2001 Feb;50(1):25-30 [11268559.001]

[Cites] East Mediterr Health J. 1999 Jan;5(1):14-20 [10793776.001]

[Cites] Nutrition. 1999 Nov-Dec;15(11-12):829-33 [10575656.001]

[Cites] J Mol Endocrinol. 1999 Apr;22(2):173-84 [10194520.001]

[Cites] Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:22-8 [10193858.001]

[Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]

[Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Diabet Med. 1995 Dec;12(12):1122-5 [8750224.001]

(PMID = 21748132.001).

[ISSN] 2075-051X

[Journal-full-title] Sultan Qaboos University medical journal

[ISO-abbreviation] Sultan Qaboos Univ Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Oman

[Other-IDs] NLM/ PMC3074914

[Keywords] NOTNLM ; Body Mass Index / Body weight / Leptin / Obesity / Oman

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women.

OBJECTIVE: The aim of this study was to evaluate the effects of estrogen-progestin therapy on serum levels of receptor-activating nuclear factor kappabeta ligand (RANKL), osteoprotegerin, osteocalcin, leptin, and ghrelin in a cross-sectional study of 99 healthy postmenopausal women conducted at the Menopause Clinic of our department.

Serum leptin levels were significantly lower in group B than in group A, whereas ghrelin was significantly higher in group B than in group A.

Similarly, although several reports suggest that leptin and ghrelin are involved in bone metabolism, we could not detect any important correlation of these two hormones with bone metabolism or bone status in treated and untreated postmenopausal women.

[MeSH-minor] Administration, Cutaneous. Bone Density / drug effects. Cross-Sectional Studies. Female. Finger Phalanges / ultrasonography. Ghrelin. Humans. Leptin / blood. Middle Aged. Osteocalcin / blood. Osteoporosis / prevention & control. Peptide Hormones / blood. Receptors, Leptin

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Menopause. 2007 Jan-Feb;14(1):7-9 [17194959.001]

(PMID = 17075432.001).

[ISSN] 1072-3714

[Journal-full-title] Menopause (New York, N.Y.)

[ISO-abbreviation] Menopause

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Estrogens; 0 / Ghrelin; 0 / Leptin; 0 / Osteoprotegerin; 0 / Peptide Hormones; 0 / Progestins; 0 / RANK Ligand; 0 / Receptors, Leptin; 0 / leptin receptor, human; 104982-03-8 / Osteocalcin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

BACKGROUND: Leptin, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

We aimed to define adipokine serum levels in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).

Serum leptin, adiponectin, and resistin levels were measured, and histology was assessed using Brunt's and Kleiner's scoring systems.

RESULTS: Waist/hip ratio was significantly higher in men (p = 0.0001), and leptin (p = 0.036) and adiponectin (p = 0.0001) serum levels were higher in women.

In NAFLD patients, serum adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while leptin was not related to histology.

Leptin/adiponectin ratio showed positive association with stage (p = 0.044).

In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between leptin, resistin, or leptin/adiponectin and histology.

CONCLUSIONS: Serum adiponectin and resistin levels are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively.

Serum leptin levels are not informative of underlying liver histology in severely obese patients.

MedlinePlus Health Information. consumer health - Hepatitis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]

[Cites] Am J Gastroenterol. 1999 Sep;94(9):2467-74 [10484010.001]

[Cites] Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21 [17331160.001]

[Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]

[Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]

[Cites] Am J Gastroenterol. 2006 Nov;101(11):2629-40 [16952281.001]

[Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5122-5 [16968796.001]

[Cites] Dig Dis Sci. 2008 Apr;53(4):1088-92 [17934820.001]

[Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]

[Cites] Hepatology. 2008 Feb;47(2):484-92 [18220286.001]

[Cites] Curr Opin Clin Nutr Metab Care. 2008 May;11(3):267-74 [18403923.001]

[Cites] Expert Rev Mol Diagn. 2007 Mar;7(2):195-205 [17331066.001]

[Cites] Surg Endosc. 2007 Sep;21(9):1593-9 [17294310.001]

[Cites] Hepatology. 2002 Aug;36(2):403-9 [12143049.001]

[Cites] Clin Endocrinol (Oxf). 2006 Jun;64(6):679-83 [16712671.001]

[Cites] Curr Opin Lipidol. 2006 Apr;17(2):170-5 [16531754.001]

[Cites] Gastroenterology. 2006 Sep;131(3):934-45 [16952562.001]

[Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]

[Cites] Obes Surg. 2005 Feb;15(2):228-37 [15802066.001]

[Cites] Gastroenterology. 2006 May;130(6):1848-52 [16697746.001]

[Cites] Obes Surg. 2008 Nov;18(11):1430-7 [18500507.001]

[Cites] Am J Gastroenterol. 2003 Dec;98(12):2771-6 [14687831.001]

[Cites] Liver Int. 2006 Mar;26(2):151-6 [16448452.001]

[Cites] Obes Surg. 2005 Mar;15(3):310-5 [15826462.001]

[Cites] J Hepatol. 2006 Oct;45(4):600-6 [16899321.001]

[Cites] Mediators Inflamm. 2006;2006(6):34295 [17392582.001]

[Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]

[Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]

[Cites] Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21 [18081738.001]

[Cites] Hepatology. 2005 Aug;42(2):490-2 [15977205.001]

[Cites] Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi [17544979.001]

[Cites] Obes Surg. 2006 Oct;16(10):1351-8 [17059746.001]

[Cites] J Hepatol. 2004 Dec;41(6):943-9 [15582127.001]

[Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504 [15797948.001]

[Cites] Obes Surg. 2006 Dec;16(12):1584-93 [17217634.001]

[Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]

[Cites] Scand J Gastroenterol. 2008;43(9):1128-36 [18609175.001]

[Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1512-6 [17708287.001]

[Cites] Hepatology. 2003 May;37(5):1202-19 [12717402.001]

[Cites] Hepatology. 2007 Aug;46(2):582-9 [17661414.001]

[Cites] Hepatology. 2007 Sep;46(3):716-22 [17659597.001]

[Cites] Gut. 2005 Jan;54(1):117-21 [15591515.001]

[Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1844-8 [15070954.001]

[Cites] Am J Gastroenterol. 2007 Feb;102(2):399-408 [17311652.001]

[Cites] Obes Surg. 2000 Aug;10(4):378-9 [11202981.001]

[Cites] Gastroenterology. 2008 May;134(6):1682-98 [18471547.001]

[Cites] Med Clin North Am. 2007 Nov;91(6):1125-49, ix [17964913.001]

[Cites] J Appl Physiol (1985). 1988 Feb;64(2):529-34 [3372410.001]

[Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1081-6 [16394091.001]

[Cites] J Hepatol. 2008 May;48(5):829-34 [18321606.001]

[Cites] Scand J Gastroenterol. 2006 May;41(5):566-72 [16638699.001]

[Cites] Am J Gastroenterol. 2007 Sep;102(9):1931-8 [17511754.001]

[Cites] J Pediatr Endocrinol Metab. 2004 Aug;17(8):1069-75 [15379417.001]

[Cites] Curr Opin Gastroenterol. 2007 Mar;23(2):193-8 [17268250.001]

[Cites] Hepatology. 2005 Nov;42(5):1175-83 [16231364.001]

[Cites] Eur J Endocrinol. 2005 Jan;152(1):113-8 [15762194.001]

[Cites] Am J Clin Pathol. 2007 Nov;128(5):837-47 [17951208.001]

[Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]

(PMID = 19693638.001).

[ISSN] 0960-8923

[Journal-full-title] Obesity surgery

[ISO-abbreviation] Obes Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adipokines

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi.

The aim of the study was to evaluate the seasonal variation in serum leptin levels in a natural population of the female bat, Scotophilus heathi and their relationship to the changes in the body mass, serum insulin level, and ovarian activity.

Circulating leptin level varied significantly over the season and correlated positively with the changes in body mass, and circulating insulin and androstenedione (A4) levels.

Circulating leptin concentrations showed two peaks; one coincides with the maximum fat accumulation prior to winter dormancy, whereas the second shorter peak coincides with late pregnancy.

The in vivo study in S. heathi showed that the increased circulating leptin level during winter dormancy coincides with the decreased expression of ovarian steroidogenic acute regulatory (StAR) protein, and low circulating estradiol (E2) level.

At the same time, increased circulating leptin level coincides with increased expression of ovarian insulin receptor and high circulating A4 level.

The low circulating leptin level during preovulatory period coincides with the increase in StAR protein but decrease in insulin receptor protein.

The in vitro study confirmed the in vivo observations of inhibitory effect of leptin on LH induced StAR expression and E2 production, whereas the stimulatory effect of leptin (high dose) on LH induced expression of insulin receptor protein and A4 production.

However, pharmacological dose of leptin produced inhibitory effect on the expression of insulin receptor protein.

The results of the present study thus suggest that high circulating leptin level during winter dormancy promotes adiposity and impairs ovarian activity by suppressing StAR-mediated E2 production as well as by enhancing insulin receptor-mediated A4 synthesis thereby contributing anovulatory condition of delayed ovulation in S. heathi.

[MeSH-major] Adiposity / physiology. Chiroptera / metabolism. Hibernation / physiology. Leptin / blood. Ovary / metabolism

Hazardous Substances Data Bank. ESTRADIOL .

Hazardous Substances Data Bank. PROGESTERONE .

Hazardous Substances Data Bank. ANDROSTENEDIONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17244743.001).

[ISSN] 1470-1626

[Journal-full-title] Reproduction (Cambridge, England)

[ISO-abbreviation] Reproduction

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Insulin; 0 / Leptin; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 409J2J96VR / Androstenedione; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EC 2.7.10.1 / Receptor, Insulin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer].

Leptin, a protein produced by adipocytes, is an important signalling molecule in energy regulation, metabolism of fatty acids and it can also augment tumour growth of various cancer cell lines.

METHODS AND RESULTS: In this study we examined the nutritional status (pre-treatment weight-loss, actual weight, body mass index), serum levels of leptin, soluble leptin receptor, TNF-alpha, IGF-1 and plasma phosphatidyl-cholin fatty acids before the beginning of treatment, after the onset of treatment and shortly before its completion.

Concomitant chemoradiation led to transient elevation of serum leptin level despite the weight loss during chemoradiotherapy.

[MeSH-major] Esophageal Neoplasms / blood. Fatty Acids / blood. Leptin / blood. Receptors, Cell Surface / blood

[MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Phosphatidylcholines / chemistry. Receptors, Leptin. Tumor Necrosis Factor-alpha / analysis. Weight Loss

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16389753.001).

[ISSN] 0008-7335

[Journal-full-title] Casopís lékar̆ů c̆eských

[ISO-abbreviation] Cas. Lek. Cesk.

[Language] cze

[Publication-type] English Abstract; Journal Article

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / Fatty Acids; 0 / Leptin; 0 / Phosphatidylcholines; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; 0 / leptin receptor, human; 67763-96-6 / Insulin-Like Growth Factor I

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have previously shown that the ratio of n-6 to n-3 polyunsaturated fatty acids (PUFA) in the maternal diet affects serum leptin levels and growth of the suckling pups.

The aim of the present study was to investigate the long-term effects of various ratios of the dietary n-6 and n-3 PUFA during the perinatal period on serum leptin, insulin, and triacylglycerol, as well as body growth in the adult offspring.

At 3 wk of age, the n-6/n-3 PUFA ratios in the serum phospholipids of the offspring were 2.5, 8.3, and 17.5, respectively.

At the 28th postnatal wk, mean body weight and fasting insulin levels were significantly increased in the rats fed the n-6/n-3 diet perinatally compared with the other groups.

The systolic blood pressure and serum triacylglycerol levels were only increased in adult male rats of the same group.

MedlinePlus Health Information. consumer health - Seniors' Health.

Hazardous Substances Data Bank. CHOLESTEROL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1564

(PMID = 15699360.001).

[ISSN] 0363-6119

[Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology

[ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Fatty Acids; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Insulin; 0 / Phospholipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Increased levels of interleukin-6 (IL-6) have been demonstrated in sputum and serum of COPD patients.

Wild-type (WT) and IL-6 knockout (KO) mice were exposed subacutely (4 weeks) and chronically (24 weeks) to air or cigarette smoke (CS).

Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein levels in bronchoalveolar lavage fluid of WT mice.

Remarkably, air-exposed IL-6 KO mice have lower body weight, serum leptin levels, and adipose tissue mass compared to air-exposed WT mice.

[MeSH-minor] Adipose Tissue, White / drug effects. Adipose Tissue, White / metabolism. Animals. Bronchoalveolar Lavage Fluid / cytology. Cell Count. Cytokines / genetics. Cytokines / metabolism. Disease Models, Animal. Gene Expression / drug effects. Leptin / genetics. Leptin / metabolism. Lymphocytes / drug effects. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Mice. Mice, Knockout. RNA, Messenger / metabolism. Smoking / adverse effects. Tobacco Smoke Pollution / adverse effects

MedlinePlus Health Information. consumer health - COPD.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20939756.001).

[ISSN] 1521-0499

[Journal-full-title] Experimental lung research

[ISO-abbreviation] Exp. Lung Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Leptin; 0 / RNA, Messenger; 0 / Tobacco Smoke Pollution

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: The nutritional status of newly diagnosed CD was assessed by anthropometry, Bioelectrical Impedance and serum leptin levels, and contrasted to age and gender matched controls.

Mean height and weight for age, other nutritional parameters and serum leptin did not differ between the groups.

Serum leptin correlated with BMI in both groups.

Variations in nutrition (under to overnutrition) may be seen at diagnosis, without relationship to the presence of symptoms.

Leptin levels were not altered specifically in the setting of CD.

[MeSH-minor] Adolescent. Anthropometry. Case-Control Studies. Child. Child, Preschool. Electric Impedance. Female. Humans. Infant. Leptin / blood. Male. Nutrition Assessment

MedlinePlus Health Information. consumer health - Celiac Disease.

MedlinePlus Health Information. consumer health - Child Nutrition.

MedlinePlus Health Information. consumer health - Toddler Nutrition.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20178518.001).

[ISSN] 1651-2227

[Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)

[ISO-abbreviation] Acta Paediatr.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Norway

[Chemical-registry-number] 0 / Leptin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leptin levels in thyroid cancer.

BACKGROUND: Leptin has physiological roles in multiple systems, and has possible effects on several carcinogenesis steps.

The aim of this study was to investigate the leptin levels in thyroid papillary carcinoma (TPC) patients.

TPC patients had a bilateral total thyroidectomy operation and their leptin levels were measured before and 20 days after the operation.

RESULTS: Serum leptin levels of TPC patients were higher than in control group subjects (21.15 +/- 14.12 ng/mL vs. 9.89 +/- 0.21 ng/mL, p < 0.05).

The leptin levels decreased after total thyroidectomy (13.92 +/- 10.55 ng/mL) compared to prethyroidectomy levels (22.94 +/- 14.67 ng/mL) in 34 patients who came to the follow-up visit (p < 0.05).

However, the decreased post-thyroidectomy levels of leptin were still statistically significantly higher than the control group levels.

Multivariate regression analysis showed that the leptin levels in TPC patients were not related to age, menopausal status or pathologic occult status but were directly related to the cancer group.

CONCLUSION: Leptin levels were elevated in thyroid cancer, decreased after total thyroidectomy, and might be associated with thyroid papillary carcinogenesis.

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19892624.001).

[ISSN] 0219-3108

[Journal-full-title] Asian journal of surgery

[ISO-abbreviation] Asian J Surg

[Language] ENG

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Leptin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease.

BACKGROUND: Recent studies have provided evidence that leptin has significant effects on vascular development and repair.

The aim was to determine the levels of leptin and lipid profile in diabetic postmenopausal women with and without the complication of ischemic heart disease and to develop correlation between them.

Moreover, the relationship between leptin levels and extent of ischemic changes were determined.

The first group comprised normal healthy controls, the second diabetic type 2 patients with no history of ischemic heart disease (I1ID), and the third diabetic patients with IHD.

Serum leptin levels were determined by a Kit obtained from DRG and samples were analyzed on ELISA.

RESULTS: The results show that leptin and serum lipid levels increased significantly in diabetic patients with IHD compared with diabetic patients without IHD as well as normal subjects.

Moreover; the sertum leptin level increased significantly in the diabetic patients with IHD who had positive findings in myocardial perfusion scan compared with those having negative findings.

CONCLUSIONS: Hyperleptinemia in diabetic patients shows that leptin contributes to the development of cardiovascular disease in diabetic patients.

[MeSH-major] Diabetes Mellitus, Type 2 / blood. Hyperlipidemias / complications. Leptin / blood. Myocardial Ischemia / etiology. Postmenopause / blood

Genetic Alliance. consumer health - Heart Disease.

MedlinePlus Health Information. consumer health - Diabetes Type 2.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16940932.001).

[ISSN] 1234-1010

[Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research

[ISO-abbreviation] Med. Sci. Monit.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Poland

[Chemical-registry-number] 0 / Leptin; 0 / Lipids

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.

BACKGROUND: Although studies comparing conventional imaging modalities with (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) for the detection of lymphoma and although the relations between (18)F-FDG-PET and histologic types were reported previously, most studies were not systematic and involved relatively small numbers of patients.

METHODS: Two hundred fifty-five patients with lymphoma had their disease staged using (18)F-FDG-PET, and 191 of those patients also were assessed using gallium-67 scintigraphy ((67)Ga).

The results of these conventional imaging modalities were compared with the results from (8)F-FDG-PET and (67)Ga, and correlations between the imaging results and pathologic diagnoses were evaluated by using the World Health Organization classification system.

RESULTS: Of 913 disease sites in 255 patients, (18)F-FDG-PET identified >97% of disease sites of Hodgkin lymphoma (HL) and aggressive and highly aggressive non-Hodgkin lymphoma.

For indolent lymphoma, the detection rate of (18)F-FDG-PET was 91% for follicular lymphoma (FL); 82% for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, irrespective of plasmacytic differentiation; and approximately 50% for small lymphocytic lymphoma (SLL) and splenic marginal zone lymphoma (SMZL).

However, the sensitivity of (67)Ga was unexpectedly poor for FL, for mantle cell lymphoma (MCL), and for the nasal type of natural killer/T-cell lymphoma (NK/T-nasal), ranging from 30% to 38%.

CONCLUSIONS: (18)F-FDG-PET was useful for all histologic subtypes of lymphoma other than SLL and SMZL.

[MeSH-major] Fluorodeoxyglucose F18. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods

[MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging / methods. Sensitivity and Specificity. World Health Organization

MedlinePlus Health Information. consumer health - Hodgkin Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 American Cancer Society.

(PMID = 17582800.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.

This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.

This program is well tolerated with a high CR rate, and may serve as a basis for future trials.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

[MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19622463.001).

[ISSN] 1973-9478

[Journal-full-title] Journal of chemotherapy (Florence, Italy)

[ISO-abbreviation] J Chemother

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone